-+ 0.00%
-+ 0.00%
-+ 0.00%

Quince Therapeutics prices private placement raising up to $187 million

PUBT·05/18/2026 13:34:33
Listen to the news
Quince Therapeutics prices private placement raising up to $187 million
  • Quince Therapeutics entered a private placement to raise up to USD 187 million in gross proceeds tied to an unregistered sale of Series C non-voting convertible preferred stock.
  • The deal includes USD 115 million of upfront proceeds, with up to about USD 72 million more available from warrant exercises.
  • Balyasny Asset Management led the financing, with participation from several other healthcare-focused investors.
  • Proceeds, together with cash at closing, are expected to fund operations through end-2028, supporting LAM-001 development with Phase 2 BOS data targeted for Q1 2027 and Phase 2b PH-ILD data targeted for Q1 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-228133), on May 18, 2026, and is solely responsible for the information contained therein.